• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Werewolf Therapeutics, Inc. - Common Stock (NQ:HOWL)

0.6400 -0.0200 (-3.03%)
Official Closing Price Updated: 4:15 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Werewolf Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
February 24, 2026
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Announces Pipeline and Business Updates
December 18, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
November 07, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 04, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
October 08, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
October 03, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
July 09, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in the BIO International Convention
June 12, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
May 29, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
May 20, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
May 13, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
May 05, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
May 05, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
April 17, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 11, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
March 04, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
February 24, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
January 13, 2025
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
November 20, 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
November 07, 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 07, 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
October 31, 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
October 04, 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
June 25, 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap